- Home
- EVER vs VIR Comparison
EVER vs VIR Comparison
Compare EVER & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVER | VIR |
|---|---|---|
| Founded | 2008 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 929.5M | 1.5B |
| IPO Year | 2018 | 2019 |
Fundamental Metrics
Financial Performance| Metric | EVER | VIR |
|---|---|---|
| Price | $15.75 | $9.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $27.00 | $19.63 |
| AVG Volume (30 Days) | 1.0M | ★ 4.6M |
| Earning Date | 05-25-2026 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 198.86 | 17.49 |
| EPS | ★ 2.63 | N/A |
| Revenue | ★ $163,349,000.00 | $68,556,000.00 |
| Revenue This Year | $14.68 | N/A |
| Revenue Next Year | $11.86 | $925.73 |
| P/E Ratio | $6.27 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.93 | $4.16 |
| 52 Week High | $30.03 | $10.91 |
Technical Indicators
Market Signals| Indicator | EVER | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 39.22 | 60.24 |
| Support Level | $13.93 | $4.88 |
| Resistance Level | $17.59 | $10.91 |
| Average True Range (ATR) | 0.78 | 0.67 |
| MACD | 0.29 | -0.03 |
| Stochastic Oscillator | 30.81 | 44.97 |
Price Performance
Historical ComparisonAbout EVER EverQuote Inc.
EverQuote Inc is engaged in the business activity of offering an online marketplace for insurance shopping, connecting consumers with insurance provider customers, which includes both carriers and agents. The online marketplace offers consumers to find relevant insurance quotes based on car insurance, home insurance, and life insurance. The platform of the company is driven by data science. The firm's data and technology platform match and connects consumers seeking to purchase insurance with relevant options from its broad direct network of insurance providers. It derives a majority of revenue from Direct channels.
About VIR Vir Biotechnology Inc.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.